awmsg logo



dulaglutide (Trulicity®)


Reference No. 866

Publication date:
15/06/2016


Appraisal information

dulaglutide (Trulicity®) 0.75 mg solution for injection
dulaglutide (Trulicity®) 1.5 mg solution for injection


Company: Eli Lilly & Co Ltd
BNF category: Endocrine system
NMG meeting date: 13/04/2016
AWMSG meeting date: 18/05/2016
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1116
Ministerial ratification: 10/06/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Dulaglutide (Trulicity®) is recommended as an option for restricted use within NHS Wales. Dulaglutide (Trulicity®) should be restricted for use in the following subpopulation/circumstances within its licensed indication for the treatment of type 2 diabetes in adults to improve glycaemic control: After failure, intolerance or where there is a contraindication to, standard triple therapy (metformin and two other antidiabetic medicines) as an alternative to insulin therapy. In combination with other glucose-lowering medicinal products but not including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control, in line with current NICE guidance. Dulaglutide (Trulicity®) is not recommended for use within NHS Wales outside of this subpopulation/these circumstances.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download